Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Cyclacel Pharmaceuticals, under license from Sankyo Co, is developing the prodrug sapacitabine for the potential treatment of cancer. Sankyo initiated phase I trials prior to Cyclacel's acquisition, and phase Ib trials are currently in progress.